^
Association details:
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Gastric Cancer)
New
Excerpt:
Herceptin should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Excerpt:
...- Patients must have a histologically proven Her2 overexpressing malignancy as determined by any standardized assay currently in clinical use...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

HER2/neu-directed therapy for biliary tract cancer

Excerpt:
Nine patients with gallbladder cancer...had received HER2/neu-directed therapy (trastuzumab, lapatinib, or pertuzumab)…All other cases had HER2/neu amplification or overexpression....In all these cases, trastuzumab was associated with partial response (n = 4), stable disease (n = 3), or complete response (n = 1).
DOI:
10.1186/s13045-015-0155-z